Recombinant Human Integrin alpha 4 beta 7/LPAM 1 Protein, CF

Recombinant Human Integrin alpha 4 beta 7/LPAM-1 Fc Chimera Protein (Catalog # 11509-A3) binds Recombinant Human MAdCAM-1 Fc Chimera (6056-MC) with an ED50 of 30.0‑450 ng/mL.

2 μg/lane of Recombinant Human Integrin alpha 4 beta 7/LPAM‑1 Fc Chimera Protein (Catalog # 11509-A3) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 115-135 kDa (Integrin beta 7) & 140-160 kDa (Integrin alpha 4), under reducing conditions and 250-280 kDa under non-reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Integrin alpha 4 beta 7/LPAM 1 Protein, CF Summary

• Additional Information: Fc Chimera
• Details of Functionality: Measured by its binding ability in a functional ELISA. Recombinant Human Integrin alpha 4 beta 7/LPAM-1 Fc Chimera (Catalog # 11509-A3) binds Recombinant Human MAdCAM-1 Fc Chimera (Catalog # 6056-MC) with an ED₅₀ of 30.0-450 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human Integrin alpha 4 beta 7/LPAM-1 protein
  

  Human ITGA4 (Tyr34-Gln970,R591L & R878Q) Accession # P13612.3	IEGR	Human IgG1 (Glu99-Lys330) (with modifications)
  Human ITGB7 (Glu20-His723) Accession # P26010.1	IEGR	Human IgG1 (Glu99-Lys330) (with modifications)
  N-terminus		C-terminus

• Accession #: P13612.3 (Integrin alpha 4) & P26010.1 (Integrin b
• N-terminal Sequence: Tyr34 (Integrin alpha 4) & Glu20 (Integrin beta 7)
• Structure / Form: Disulfide-linked heterodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 130 kDa (Integrin alpha 4) & 104 kDa (Integrin beta 7).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 115-135 kDa (Integrin beta 7) & 140-160 kDa (Integrin alpha 4), under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Integrin alpha 4 beta 7/LPAM 1 Protein, CF

• 269C wild type
• CD49 antigen-like family member D
• CD49d antigen
• CD49d
• CD49d/beta7
• CD49Dantigen CD49D, alpha-4 subunit of VLA-4 receptor
• IA4
• Integrin alpha 4 beta 7
• integrin alpha 4
• integrin alpha-4 subunit
• integrin alpha-4
• Integrin alpha-IV
• integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
• LPAM1
• LPAM-1
• MGC90518
• very late activation protein 4 receptor, alpha 4 subunit
• VLA-4 subunit alpha

Background

Integrin alpha 4 beta 7 is an integrin family adhesion receptor that shares subunits with alpha 4 beta 1 (VLA4) and the E-Cadherin receptor, alpha E beta 7 (1). It is a non-covalent heterodimer composed of two type I transmembrane glycoprotein subunits, a 150 kDa alpha 4 (CD49d) subunit and a 130 kDa beta 7 subunit (2, 3). The alpha 4 extracellular domain (ECD) contains an N-terminal beta -propeller structure followed by thigh, calf-1, and calf-2 domains (1). The beta 7 ECD contains a vWFA domain, which interacts with the
alpha 4 beta -propeller to form a binding domain. Metal ion binding sites termed MIDAS and LIMBS promote firm adhesion, and another site termed ADMIDAS is a negative regulatory site that promotes rolling (4-6). The human alpha 4 ECD shares 85% amino acid sequence identity with the mouse, rat, and canine alpha 4 ECD. The human beta 7 ECD shares 88% and 87% amino acid sequence identity with the rat and mouse beta 7 ECD, respectively. Integrin alpha 4 beta 7 binds the mucosal addressin MAdCAM-1, as well as VCAM-1 and Fibronectin (7). Integrin alpha 4 beta 7, which is critical for homing to intestinal mucosa, is induced during T cell activation in Peyer’s patches or mesenteric lymph nodes (8, 9). Its expression requires signals from local dendritic and stromal cells, including secreted retinoic acid (10, 11). The HIV-1 envelope protein gp120 binds to the active form of Integrin alpha 4 beta 7, and this may or may not account for the concentration of HIV-1 virus in the gut-associated lymphoid tissue (GALT) (12-14). Integrin  alpha 4 beta 7 may also be involved in lymphocyte trafficking in acute intestinal graft vs. host disease (GVHD) (15).

1. Luo, B.H. et al. (2007) Annu. Rev. Immunol. 25:619.
2. Takada, Y. et al. (1989) EMBO J. 8:1361.
3. Erle, D.J. et al. (1991) J. Biol. Chem. 266:11009.
4. Chen, J. et al. (2004) J. Biol. Chem. 279:55556.
5. Park, E.J. et al. (2007) J. Clin. Invest. 117:2526.
6. Yu, Y. et al. (2012) J. Cell Biol. 196:131.
7. Yang, Y. et al. (1998) Eur. J. Immunol. 28:995.
8. Wagner, N. et al. (1996) Nature 382:366.
9. Johansson-Lindbom, B. and W.W. Agace (2007) Immunol. Rev. 215:226.
10. Hammerschmidt, S.I. et al. (2008) J. Exp. Med. 205:2483.
11. Edele, F. et al. (2008) J. Immunol. 181:3745.
12. Arthos, J. et al. (2008) Nat. Immunol. 9:301.
13. Cicala, C. et al. (2009) Proc. Natl. Acad. Sci. USA 106:20877.
14. Monteiro, P. et al. (2011) J. Immunol. 186:4618.
15. Chen, Y.B. et al. (2013) Bone Marrow Transplant. 48:598.

Bioinformatics

• Uniprot:
  • P13612.3 (Integrin alpha 4) & P26010.1 (Integrin b()